Patent · US Active

Rapid acting and long acting insulin combination formulations

US7718609B2 · kind B2 · utility

11Cited by
106References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 11, 2007
Grant dateMay 18, 2010
Priority date—
Expiry dateAug 30, 2027

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/183
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A combined rapid acting-long acting insulin formulation has been developed in which the pH of the rapid acting insulin is adjusted so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.